Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous bone marrow intramyocardial injection for severe coronary artery disease with chronic ischaemic heart failure
ACTRN12611000219987Phase 2Withdrawn
- Sponsor
- John Hunter Hospital
- Start
- May 2011
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of autologous bone marrow-derived mononuclear cell in heart failure (HF) and coronary arteriosclerosis (2 arms), sponsored by John Hunter Hospital. Primary endpoint: Left ventricular ejection fraction. Planned start May 2011; status: withdrawn.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
heart failure (HF)coronary arteriosclerosis
Beyond the preview
Go deeper on ACTRN12611000219987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000219987.